Suppr超能文献

狼疮性膜性肾病

Lupus Membranous Nephropathy.

作者信息

Ponticelli Claudio, Moroni Gabriella, Fornoni Alessia

机构信息

Nephrology, IRCCS Ospedale Maggiore Policlinico (retired), Milan, Italy.

Nephrology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Milano, Milan, Italy.

出版信息

Glomerular Dis. 2021 Mar 2;1(1):10-20. doi: 10.1159/000512278. eCollection 2021 Apr.

Abstract

BACKGROUND

Lupus membranous nephropathy (LMN) is a rare disease, usually associated with nephrotic syndrome.

METHODS

We reviewed the literature by searching for the following terms on Pubmed.gov: lupus nephritis, membranous nephropathy (MN), lupus membranous nephropathy, nephrotic syndrome, and Class V lupus nephritis.

RESULTS

The histology of LMN at light microscopy is similar to that of primary MN. Cases of MN associated with focal or diffuse proliferation are not considered LMN by the International Society of Nephrology/Renal Pathology Society classification. Immunofluorescence study of LMN shows deposits of all immunoglobulins and complement. Tubulo-reticular structures, extraglomerular deposits, subepithelial, and scanty subendothelial deposits can be seen on electron microscopy. Phospholipase A2 receptor deposits are usually but not necessarily absent in LMN. The pathogenesis is still not completely understood. The inflammatory milieu of lupus may favor the development of autoantigens and intraglomerular assembly of immune complexes. These are more often associated with mesangial or endocapillary hypercellular lesions. Alternatively, autoantibodies may bind autoantigens in the glomerular subepithelium, triggering a signaling cascade leading to LMN. A central role in the development of podocyte injury and proteinuria is played by the components of complement C5b-C9. CKD progression in LMN is slow but may be accelerated by the frequency of renal flares. Persistent nephrotic syndrome and/or the frequent use of corticosteroids may lead to a series of life-threatening complications.

DISCUSSION

Treatment of arterial hypertension, dyslipidemia, and diabetes are of paramount importance. Besides specific therapies of these complications, hydroxychloroquine and vitamin D supplementation are recommended. Immunosuppression should be limited to patients with nephrotic proteinuria. The most frequently used drugs are corticosteroids, calcineurin inhibitors, cyclophosphamide, mycophenolate, and rituximab, alone or combined. Early detection and treatment of renal flares is of paramount importance to prevent CKD progression.

摘要

背景

狼疮性膜性肾病(LMN)是一种罕见疾病,通常与肾病综合征相关。

方法

我们通过在Pubmed.gov上搜索以下术语来回顾文献:狼疮性肾炎、膜性肾病(MN)、狼疮性膜性肾病、肾病综合征和Ⅴ型狼疮性肾炎。

结果

LMN在光学显微镜下的组织学表现与原发性MN相似。国际肾脏病学会/肾脏病理学会分类不将伴有局灶性或弥漫性增殖的MN病例视为LMN。LMN的免疫荧光研究显示所有免疫球蛋白和补体的沉积。在电子显微镜下可见管周网状结构、球外沉积物、上皮下和少量内皮下沉积物。磷脂酶A2受体沉积物在LMN中通常但不一定不存在。其发病机制仍未完全明确。狼疮的炎症环境可能有利于自身抗原的产生和免疫复合物在肾小球内的组装。这些情况更常与系膜或毛细血管内细胞增多性病变相关。或者,自身抗体可能与肾小球上皮下的自身抗原结合,触发信号级联反应导致LMN。补体C5b - C9成分在足细胞损伤和蛋白尿的发生中起核心作用。LMN中慢性肾脏病的进展缓慢,但肾活动期的发作频率可能会加速其进展。持续性肾病综合征和/或频繁使用糖皮质激素可能导致一系列危及生命的并发症。

讨论

动脉高血压、血脂异常和糖尿病的治疗至关重要。除了对这些并发症进行特定治疗外,建议使用羟氯喹和补充维生素D。免疫抑制应仅限于患有肾病性蛋白尿的患者。最常用的药物是糖皮质激素、钙调神经磷酸酶抑制剂、环磷酰胺、霉酚酸酯和利妥昔单抗,可单独使用或联合使用。早期发现和治疗肾活动期对于预防慢性肾脏病进展至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7b8/9677716/31d398d99d3f/gdz-0001-0010-g01.jpg

相似文献

1
Lupus Membranous Nephropathy.
Glomerular Dis. 2021 Mar 2;1(1):10-20. doi: 10.1159/000512278. eCollection 2021 Apr.
4
Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy.
Lupus Sci Med. 2023 Dec 28;10(2):e001051. doi: 10.1136/lupus-2023-001051.
5
Advances in Membranous Nephropathy.
J Clin Med. 2021 Feb 5;10(4):607. doi: 10.3390/jcm10040607.
6
Therapy of membranous nephropathy in systemic lupus erythematosus.
Semin Nephrol. 2003 Jul;23(4):386-91. doi: 10.1016/s0270-9295(03)00056-1.
7
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.
Kidney Int. 2021 Jul;100(1):171-181. doi: 10.1016/j.kint.2020.09.016. Epub 2020 Oct 9.
8
The Prevalence of Mesangial Electron-Dense Deposits in PLA2R-Positive Membranous Nephropathy.
Nephron. 2022;146(2):167-171. doi: 10.1159/000519912. Epub 2021 Nov 19.
10
Lupus-like membranous nephropathy. Is it lupus? Report of 5 cases in a reference hospital in Mexico.
Lupus. 2021 Jul;30(8):1347-1357. doi: 10.1177/09612033211013584. Epub 2021 May 12.

引用本文的文献

1
Membranous Nephropathy.
J Clin Med. 2025 Jan 24;14(3):761. doi: 10.3390/jcm14030761.
2
II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.
Adv Rheumatol. 2024 Jun 18;64(1):48. doi: 10.1186/s42358-024-00386-8.
3
Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.
Adv Immunol. 2021;152:1-81. doi: 10.1016/bs.ai.2021.09.001. Epub 2021 Nov 19.

本文引用的文献

2
Role of direct oral anticoagulants in patients with kidney disease.
Kidney Int. 2020 Apr;97(4):664-675. doi: 10.1016/j.kint.2019.11.027. Epub 2019 Dec 24.
3
The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future.
Adv Chronic Kidney Dis. 2019 Sep;26(5):360-368. doi: 10.1053/j.ackd.2019.08.015.
4
Systemic Lupus Erythematosus and DNA Degradation and Elimination Defects.
Front Immunol. 2019 Aug 7;10:1697. doi: 10.3389/fimmu.2019.01697. eCollection 2019.
5
Renal flare in class V lupus nephritis: increased risk in patients with tubulointerstitial lesions.
Rheumatol Int. 2019 Dec;39(12):2061-2067. doi: 10.1007/s00296-019-04369-7. Epub 2019 Jul 6.
6
Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis.
J Rheumatol. 2020 Mar;47(3):377-386. doi: 10.3899/jrheum.181232. Epub 2019 May 15.
7
Antibodies to M-type phospholipase A2 receptor (PLAR) in membranous lupus nephritis.
Lupus. 2019 Mar;28(3):396-405. doi: 10.1177/0961203319828521. Epub 2019 Feb 13.
8
Unmet challenges in membranous nephropathy.
Curr Opin Nephrol Hypertens. 2019 Jan;28(1):70-76. doi: 10.1097/MNH.0000000000000459.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验